One of the most common types of mutations in the dystrophin gene occurs when a piece of the code in the middle of the gene is missing or deleted. By skipping additional segments of the dystrophin code called exons, the deletion can shift from an out-of-frame deletion to an in-frame deletion. Typically an in-frame deletion results in a smaller, but still functional, dystrophin protein. This shortened protein is expected to act in a similar way to normal dystrophin, and so relieve some symptoms of Duchenne and hopefully result in a more mild presentation. EXONDY 51® is for use in patients with a mutation in the dystrophin gene that is amenable to exon 51 skipping.
EXONDYS 51 is indicated for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping (FDA label document). This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51. A clinical benefit of EXONDYS 51 has not been established. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.
For additional resources regarding eligibility and access, view PPMD’s Insurance Access & Coverage Roadmap.
On March 19, 2020, Sarepta Therapeutics has provided an update addressing questions from the community regarding COVID-19, including updates on current clinical trials and accessing approved therapies. On April 13, 2020, Sarepta Therapeutics shared additional COVID-19 resources.
This program is sponsored by Sarepta Therapeutics.
|A Study to Compare Safety and Efficacy of a High Dose of Eteplirsen in Duchenne Muscular Dystrophy (DMD) Patients (MIS51ON)|
|Study of Eteplirsen in Young Patients With DMD Amenable to Exon 51 Skipping|
OPEN LABEL EXTENSION
|A Study to Evaluate Safety, Tolerability, and Efficacy of Eteplirsen|
Sarepta Presents at the PPMD 2019 Annual Conference
Sarepta Presents at the PPMD 2018 Annual Conference
Webinar: Access Resource - EXONDYS 51 - California MediCal (Medicaid) PresentationDr. Craig McDonald of UC Davis has shared data and an accompanying presentation to serve as a resource for families who have received an EXONDYS 51 denial from their insurance company and are working to appeal the decision. You should insist that both your clinician and insurance company review this data and presentation. View more PPMD access resources and tools at parentprojectmd.org/accessresources.
Webinar: SareptAssist Patient Services OverviewOn September 26, 2016, Parent Project Muscular Dystrophy and Sarepta Therapeutics, Inc. hosted an informational webinar about SareptAssist, Sarepta's patient support program. To learn more visit sareptassist.com.